President Trump's "most-favored-nation" pricing push added nine more pharmaceutical companies this week, bringing the roster of participants to 26. But independent reporting shows several of the administration's dollar figures rest on shakier assumptions than the topline numbers suggest, and the Medicaid channel that carries the discounts skips over millions of Latino families in Texas and Florida who never got Medicaid expansion.
A ninth round, and a familiar promise
President Donald Trump told reporters in the Oval Office on Monday that every drug would soon be sold "at the lowest prices available anywhere in the world," extending a pricing framework the administration calls "most-favored-nation," or MFN. The newest signatories — UCB, Teva Pharmaceuticals, Sun Pharma, Kyowa Kirin, CSL, BridgeBio, BeOne Medicines, Astellas Pharma and Alcon — are mid-sized manufacturers whose product lines treat glaucoma, liver disease, several forms of cancer, hemophilia, Parkinson's disease and macular degeneration, according to the White House's own fact sheet on the agreements.
With this batch, the administration now counts 26 companies inside the framework, together representing what officials put at 89 percent of the branded U.S. drug market's value. Trump himself cited a slightly higher figure during his remarks, telling reporters the real number was closer to 90%, with the remaining slice of the market expected to fall in line eventually — a small but real gap between the president's spoken claims and his own administration's written materials, per Yahoo Finance's account of the announcement.
What the nine companies actually agreed to
Beyond the pricing pledge itself, the nine manufacturers committed a combined $19.6 billion toward near-term U.S. manufacturing, a figure carried consistently by outlets including Becker's Hospital Review, though it traces back solely to the administration's own accounting and hasn't been independently audited. Several companies also pledged raw pharmaceutical ingredients to a federal emergency stockpile, including well over 160 tons of the seizure medication levetiracetam from UCB and sizable antibiotic-ingredient donations from Sun Pharma and Teva, meant to cut U.S. dependence on foreign chemical suppliers.
In exchange, the nine companies pick up something largely missing from earlier coverage of the deal: protection from pharmaceutical tariffs and a carve-out from a parallel MFN pricing push aimed at Medicare, according to The Hill's same-day reporting. Firms that inked deals in earlier rounds already avoid a steep import duty — as much as 100% — on patented medicines through the start of 2029; manufacturers still holding out face a smaller, though still meaningful, tariff in the meantime, per Becker's Hospital Review — a trade-off that gives these voluntary pledges real financial weight, even though the pricing promises themselves carry no regulatory force.
Billions projected, but on shakier ground than the topline suggests
The administration's Council of Economic Advisers now pegs total savings from the MFN push at roughly $600 billion across the coming ten years, up from a $529 billion projection the same council published back in May. A narrower slice of that same analysis — not a separate estimate, despite how some coverage frames it — covers only the Medicaid and cash-pay channels the voluntary deals actually touch, landing at $64.3 billion over ten years, a figure several outlets including NBC News describe as speculative.
A separate review by FactCheck.org found the larger figure hinges on an assumption that MFN pricing eventually gets written into federal law and applies to every drug that launches from here forward. Yet the deals as currently structured appear tied to the length of Trump's presidency, and securities filings from at least two signing companies describe commitments running only three years — a gap between a ten-year savings pitch and contracts that may cover a fraction of that span, one the administration's own materials don't spell out for readers.
No drug has changed hands under the deals — yet
As of this week, no medication has actually been dispensed at a negotiated MFN price under the formal Medicaid agreements, The Hill reports, and the administration still hasn't shared the underlying contract language with lawmakers, leaving Congress unable to independently check whether the arrangements will actually save money. That's separate from TrumpRx, the administration's direct-to-consumer discount website, which already lists hundreds of brand-name and generic medications at negotiated cash prices — the Medicaid rebate structure central to Monday's announcement is a different, and so far still unlaunched, mechanism entirely.
Because Medicaid enrollees typically already pay only $4 to $8 out of pocket per prescription regardless of list price, one market-access analyst told Pharmaceutical Executive that most of any new savings would land in state budget ledgers rather than directly in patients' wallets. The pricing guarantees also skip the roughly 160 million Americans covered through an employer, since the deals apply only to Medicaid and direct cash purchases.
Participation isn't automatic even within Medicaid itself. Patients For Affordable Drugs noted Monday that individual states can decide whether to opt into the arrangement at all, meaning both the pace and the reach of any eventual discount will vary by where a Medicaid enrollee happens to live.
Watchdogs flag a familiar loophole
Because none of the pledges carry regulatory force, nothing stops a company from raising list prices on medicines it already sells even after signing on. A Public Citizen analysis reported by Hoodline found that all 16 companies from the program's earlier rounds nonetheless raised list prices on 272 different products in the first months of 2026 — a pattern a separate Senate review from Sen. Bernie Sanders' office reportedly reached independently. Public Citizen's Access to Medicines director, Peter Maybarduk, didn't mince words on Monday: "Trump is cozying up to Big Pharma and keeping American drug prices high," he said in a statement.
The gap between a voluntary pledge and an enforceable rule echoes an earlier Medicare pricing policy from Trump's first term, which industry lawsuits pushed federal courts to block nationwide back in 2020, before it ever took effect.
A mixed picture for diaspora communities
How far Monday's expansion reaches inside Latino communities across LatinTimes' core markets depends heavily on geography. Medicaid carries outsized weight for Latino patients nationally — Latinos made up roughly 19% of the U.S. population in 2020 but 28% of Medicaid enrollees, per federal health data. Hispanic adults were also about 13% more likely than the general population to have diabetes as of 2024, according to the HHS Office of Minority Health — a condition tied to several of the metabolic and obesity medicines the MFN program targets.
But eligibility splits sharply along state lines. New York, New Jersey, Illinois and California all expanded Medicaid years ago, while Texas and Florida — home to Houston and Miami, two of LatinTimes' five core metros — never did. Texas alone accounts for roughly 42% of the nation's estimated 1.4 million-person Medicaid coverage gap, and Florida adds close to 388,000 more residents caught in that same gap, according to state-level tracking from HealthInsurance.org. Advocates are currently pushing to place a Medicaid-expansion measure on Florida's 2026 ballot, though that same tracking notes the effort faces a difficult path toward qualifying. Many lower-income Latino residents in Houston and Miami may therefore sit entirely outside the very system through which the new discounts are supposed to flow. Nationally, the Hispanic uninsured rate has climbed to roughly 2.7 times the rate among white Americans, according to KFF.
What comes next
Trump is pressing Congress to pass the Great Healthcare Plan, broader legislation meant to write MFN-style pricing into law, cap insurance premiums and expand price transparency — the same legislative step FactCheck.org's reviewers say the administration's largest savings estimate actually depends on. Unlike the company-by-company deals announced this week, that plan needs congressional votes rather than executive negotiation, so its fate, and the durability of everything promised Monday, now rests with lawmakers. With healthcare costs ranking among voters' top concerns heading into November's midterms, the fight over drug pricing, and how unevenly its benefits reach across state lines, looks likely to stay in the headlines well into the fall.
